Drugs

, Volume 50, Issue 6, pp 991–1000 | Cite as

Guidelines for the Drug Treatment of Hypertensive Crises

  • Michael M. Hirschl
Practical Therapeutics

Summary

Hypertensive crises are a group of clinicopathological entities in which rapid reduction of hypertension is necessary to prevent serious end-organ damage. The diagnosis and treatment plan depends on the identification of specific end-organ dysfunction. The goal of treatment is to limit the progression of end-organ damage in patients with hypertensive crises. Several potent antihypertensive drugs, such as sodium nitroprusside, labetalol and urapidil, are available to produce an immediate fall in blood pressure. The choice of the drug should be made on the basis of its pharmacodynamic properties, clinical effects, advantages and contraindications. Additionally, rapid reduction of blood pressure carries a considerable risk, if it is performed in an uncontrolled manner, leading to further end-organ damage. The aim of the treatment is not just to reduce blood pressure, but to do so with minimal adverse effects while preserving organ function.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154–83.CrossRefGoogle Scholar
  2. 2.
    Kaplan NM. Management of hypertensive emergencies. Lancet 1994; 344: 1335–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Shepherd AMM, Irvine NA. Differential hemodynamic and sympathoadrenal effects of sodium nitroprusside and hydralazine in hypertensive subjects. J Cardiovasc Pharmacol 1986; 8: 527–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Gifford RW. Management of hypertensive crises. JAMA 1991; 266: 829–35.PubMedCrossRefGoogle Scholar
  5. 5.
    Prisant LM, Carr AA, Hawkins DW. Treating hypertensive emergencies: controlled reduction of blood pressure and protection of target organs. Postgrad Med 1993; 93: 92–6.PubMedGoogle Scholar
  6. 6.
    Gross G, Hanft G, Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxy-tryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch Pharmacol 1987; 336: 597–601.PubMedCrossRefGoogle Scholar
  7. 7.
    Späh F, Grosser KD, Thieme G. Acute hemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies. Drugs 1990; 40 Suppl. 4: 58–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Wang RYC, Chow JSF, Chan KH, et al. Acute hemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure. Eur Heart J 1984; 5: 745–51.PubMedGoogle Scholar
  9. 9.
    Schook CE, Radtke H, Wurst W, et al. Overview of clinical trials with urapidil. Am J Cardiol 1989; 64: 30D–7D.PubMedCrossRefGoogle Scholar
  10. 10.
    Hirschl MM, Seidler D, Zeiner A, et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med 1993; 11: 653–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Farmer JB, Kennedy I, Levy GP, et al. Pharmacology of AH5158; a drug which blocks alpha and beta adrenoceptors. Br J Pharmacol 1972; 45: 660–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Dunn FG, Oigman W, Messerli FH, et al. Hemodynamic effects of intravenous labetalol in essential hypertension. Clin Pharmacol Ther 1983; 33: 139–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Cressman MD, Vidt DG, Gifford RW, et al. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. Am Heart J 1984; 107: 980–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Garrett BN, Kaplan NM. Efficacy of slow infusion of diazoxide in the treatment of severe hypertension without organ hypoperfusion. Am Heart J 1982; 103: 390–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Huysmans FTM, Thien TA, Koene RAP. Combined intravenous administration of diazoxide and beta-blocking agent in acute treatment of severe hypertension or hypertensive crisis. Am Heart J 1982; 103: 395–400.PubMedCrossRefGoogle Scholar
  16. 16.
    Kuzniar J, Skret A, Piela A, et al. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Obstet Gynecol 1985; 66: 453–8.PubMedGoogle Scholar
  17. 17.
    Remuzzi G, Ruggenenti P. Prevention and treatment of pregnancy associated hypertension: what have we learned in the last 10 years? Am J Kidney Dis 1991; 18: 285–305.PubMedGoogle Scholar
  18. 18.
    Vidt DG. Current concepts in treatment of hypertensive emergencies. Am Heart J 1986; 111: 220–5.PubMedCrossRefGoogle Scholar
  19. 19.
    DiPette DJ, Ferraro JC, Evans RR, et al. Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor in hypertensive crises. Clin Pharmacol Ther 1985; 38: 199–204.PubMedCrossRefGoogle Scholar
  20. 20.
    Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different dosages of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med. In press.Google Scholar
  21. 21.
    Strauss R, Gavras I, Vlahakos D, et al. Enalaprilat in hypertensive emergencies. Clin Pharmacol 1986; 26: 39–43.Google Scholar
  22. 22.
    Wallin JD, Fletcher E, Ram CV, et al. Intravenous nicardipine for the treatment of severe hypertension: a double-blind, placebo-controlled multicenter trial. Arch Intern Med 1989; 149: 2262–9.CrossRefGoogle Scholar
  23. 23.
    Bussmann WD, Kenedi P, Von Mengden HJ, et al. Comparison of nitroglycerin with nifedipine in patients with hypertensive crises or severe hypertension. Clin Investig 1992; 70: 1085–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Cottrell JE, Turndorf H. Intravenous nitroglycerin. Am Heart J 1978; 96: 550–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Dale RC, Schroeder ET. Respiratory paralysis during treatment of hypertension with trimetapham camsylate. Arch Intern Med 1976; 136: 816–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Kürkcyan I, Sterz F, Roden M, et al. A new preparation of nifedipine for sublingual application in hypertensive urgencies. Angiology 1994; 45: 629–35.CrossRefGoogle Scholar
  27. 27.
    Frishman WH, Weinberg P, Peled HB, et al. Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis. Am J Med 1984; 77: 35–45.PubMedGoogle Scholar
  28. 28.
    Rohr G, Reimnitz P, Blanke P. Treatment of hypertensive emergency: comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules. Intensive Care Med 1994; 20: 268–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Healton EB, Brust JC, Feinfeld DA, et al. Hypertensive encephalopathy and the neurologic manifestations of malignant hypertension. Neurology 1982; 32: 127–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Dinsdale HB. Hypertensive encephalopathy. Stroke 1982; 13: 717–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Davalos A, Cendra E, Teruel J, et al. Deteriorating ischemie stroke: risk factors and prognosis. Neurology 1990; 40: 1865–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Barry DI. Cerebrovascular aspects of antihypertensive treatment. Am J Cardiol 1989; 63: 14C–18C.PubMedCrossRefGoogle Scholar
  33. 33.
    Phillips SJ. Pathophysiology and management of hypertension in acute ischemie stroke. Hypertension 1994; 23: 131–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Graham DI. Ischaemic brain damage following emergency blood pressure lowering in hypertensive patients. Acta Med Scand 1983; Suppl. 678: 61–9.Google Scholar
  35. 35.
    Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care: Part IV. Special resuscitation situations: stroke. JAMA 1992; 268: 2242–4.CrossRefGoogle Scholar
  36. 36.
    Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981; 246: 2177–80.PubMedCrossRefGoogle Scholar
  37. 37.
    Braunwald E. Pathophysiology of heart failure. In: Braunwald E, editor. Heart disease. Philadelphia: Saunders, 1992: 393–418.Google Scholar
  38. 38.
    Lawrence E. Left ventricular failure and aortic dissection. In: Swales JE, editor. Textbook of hypertension. Oxford: Blackwell Scientific Publications, 1994: 1248–59.Google Scholar
  39. 39.
    Gibson TC. Blood pressure levels in acute myocardial infarction. Am Heart J 1987; 96: 475–9.CrossRefGoogle Scholar
  40. 40.
    o’Mailia J, Sander G, Giles T. Nifedipine associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. Ann Intern Med 1987; 107: 185–7.PubMedGoogle Scholar
  41. 41.
    Renard M, Riviere A, Jacops P, et al. Treatment of hypertension in acute stage of myocardial infarction. Br Heart J 1983; 49: 522–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Prokop EK, Palmer RF, Wheat MW. Hemodynamic forces in dissecting aneurysms. Circ Res 1970; 27: 121–7.PubMedCrossRefGoogle Scholar
  43. 43.
    DeSanctis RW, Doroghazi RM, Austen WG, et al. Aortic dissection. N Engl J Med 1987; 317: 1060–6.PubMedCrossRefGoogle Scholar
  44. 44.
    St John Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma: review of a 50-year autopsy series. Mayo Clin Proc 1981; 56: 354–60.Google Scholar
  45. 45.
    Hauptman JB, Modlinger RS, Ertel NH. Pheochromocytoma resistant to alpha adrenergic blockade. Arch Intern Med 1983; 143: 2321–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Navaratnarajah M, White DC. Labetalol and pheochromocytoma. Br J Anaesth 1984; 56: 1179.PubMedCrossRefGoogle Scholar
  47. 47.
    Alpert M, Bauer J. Hypertensive emergencies: recognition and pathogenesis. Cardiovasc Rev Rep 1985; 6: 407–11.Google Scholar
  48. 48.
    Lindheimer MD, Katz AI. Hypertension in pregnancy. N Engl J Med 1985; 313: 675–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Gales MA. Oral antihypertensives for hypertensive urgencies. Ann Pharmacother 1994; 28: 352–8.PubMedGoogle Scholar
  50. 50.
    Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med 1991; 151: 678–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Jaker M, Atkins S, Soto M, et al. Oral nifedipine vs oral clonidine in the treatment of urgent hypertension. Arch Intern Med 1989; 149: 260–65.PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Michael M. Hirschl
    • 1
  1. 1.Department of Emergency MedicineNew General Hospital, University of ViennaViennaAustria

Personalised recommendations